The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AGX101: A TM4SF1-directed tubulin inhibitor conjugate in ongoing first-in-human trial including GI cancers.
 
Paul Jaminet
Employment - Angiex
Leadership - Angiex
Stock and Other Ownership Interests - Angiex
Patents, Royalties, Other Intellectual Property - Angiex, Inc
 
Ildefonso Rodriguez Rivera
Employment - Next Oncology; Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology
Consulting or Advisory Role - Cardinal Health; Syneos Health; Telix Pharmaceuticals; Werewolf Therapeutics
 
Shou-Ching Jaminet
Employment - Angiex
Leadership - Angiex
Stock and Other Ownership Interests - Angiex
Patents, Royalties, Other Intellectual Property - Angiex, Inc
 
Glen Weiss
Employment - Sotio
Leadership - Angiex; Quibim
Stock and Other Ownership Interests - Agenus; Aurinia Pharmaceuticals; Circulogene Theranostics; Moderna Therapeutics
Consulting or Advisory Role - Angiex; Gossamer Bio; Harvest Integrated Research Organization; IGC; Imaging Endpoints; Immunocore; Kymera; Oncacare; Sun Pharma
Patents, Royalties, Other Intellectual Property - inventor: PCT/US2008/072787, PCT/US2010/043777, PCT/US2011/020612, and PCT/US2011/037616
Expert Testimony - Wyeth
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)